Introduction. Acute myeloid leukemia (AML) in the elderly presents with peculiar characteristics, and current conventional approaches achieve only poor results, especially in relapsed patients. In particular, intensified regimens do not offer advantages in terms of clinical response, and even cause significant toxicity. Thus, alternative strategies able to combine efficacy and a low profile of ...